Melanoma drug duel: which combo boosts immunity more?

NCT ID NCT07223411

Recruiting now Knowledge-focused Sponsor: John Kirkwood Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at how two different drug combinations affect the immune system in people with advanced melanoma that cannot be removed by surgery. Researchers will compare Opdualag (nivolumab/relatlimab) with cemiplimab/fianlimab by analyzing blood and tumor samples from 20 participants. The goal is to understand which treatment triggers a stronger immune response, potentially helping doctors choose the best therapy in the future.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Opdualag (nivolumab/relatlimab) and cemiplimab/fianlimab
What this could lead to: If successful, this study could reveal which drug combination triggers a stronger immune response against melanoma, guiding future treatment choices.
What could go wrong: This is a small, early-stage translational study with only 20 participants, so results may not apply broadly. It focuses on immune markers, not direct patient outcomes like survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cutaneous melanoma metastatic melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALLY ADVANCED MELANOMA

Contacts and locations

Locations

UPMC Hillman Cancer Center
RECRUITING

Pittsburgh, Pennsylvania, 15232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.